Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




R-Biopharm and Merck Partner on Companion Diagnostics

By LabMedica International staff writers
Posted on 10 Apr 2016
R-Biopharm AG (Darmstadt, Germany) and Merck KGaA (Darmstadt, Germany) have entered into an agreement that constitutes their first collaboration, which will initially focus on developing and launching companion diagnostics.

Companion diagnostics play a central role in personalized medicine by helping to find specific therapies matching to individual patients and thereby improve patient care and reduce healthcare costs.

In addition to covering research, development, and launching of novel companion diagnostics, the project also provides a framework for further collaborations across a potentially wide range of therapeutic areas and a broad range of technologies.

"We are very pleased to partner with Merck KGaA, Darmstadt, Germany, one of the world's leading healthcare companies", said Dr. More...
Frank Apostel, vice president, Companion Diagnostics, R-Biopharm, a leading developer and provider of reliable test systems for clinical diagnostics and for analyzing human food and animal feedstuffs, "This partnership is an example to the level of expertise and service R-Biopharm is committed to delivering to our partners in companion diagnostics."

Financial terms of the agreement were not disclosed.

Related Links:

R-Biopharm
R-Biopharm Companion Diagnostics
Merck KGaA



New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.